The University of Pittsburgh’s Center for Medical Innovation awarded a total of $115,000 to advance the development of five medical innovations, including a potential therapy for pulmonary fibrosis.

One of the recipients is a group developing an early-stage inhaled aerosol delivery system to efficiently deliver a CXCL10 biomimetic peptide to the lungs.

Biomimetic peptides are synthetically produced in the lab to mimic the effects of naturally-occurring peptides (small pieces of protein). The so-called FibroKine delivery system is designed to specifically help patients with pulmonary fibrosis (PF).